Sapu Nano 推出具有广泛应用前景的 Deciparticle™ 纳米药物平台，可用于多种疏水性肽类、大环内酯类和聚酮类药物的制剂化

Core Insights - Sapu Nano has confirmed that its proprietary Deciparticle platform can provide stable and consistent formulation solutions for a variety of hydrophobic drugs, maintaining nanoparticle sizes below 20 nanometers suitable for intravenous administration [1][2] Group 1: Deciparticle Platform - The Deciparticle platform is capable of handling compact hydrophobic macrocyclic compounds and amphiphilic linear peptide molecules, which expands the development pipeline for peptide-based drugs [2] - The platform has been validated for its ability to support a diverse range of hydrophobic drugs previously limited by solubility and delivery barriers, indicating its potential as a modular nanomedicine engine [3] Group 2: cGMP Production Capabilities - Sapu Nano's ISO-5 cGMP facilities enable rapid and reliable conversion of formulations into clinical trial supplies, supporting multiple IND applications annually [3] - The cGMP infrastructure allows for high batch-to-batch reproducibility and stability of drug formulations, with precise control over particle size and consistency [4]